Literature DB >> 28246677

Tissue factor levels in type 2 diabetes mellitus.

Prashilla Soma1, Albe C Swanepoel1, Janette Bester1, Etheresia Pretorius2.   

Abstract

INTRODUCTION: Type 2 diabetes mellitus is a pandemic associated with disturbance in haemostasis that could contribute to the development of diabetic vascular disease and accelerated atherosclerosis. In this population, hypercoagulation is prevalent, as well as pathological changes to erythrocytes. This is mainly due to upregulated circulating inflammatory markers.
MATERIALS AND METHODS: Here we looked at tissue factor (TF) levels using ELISA, in a sample of diabetics, with and without cardiovascular complications. Diabetic subjects were recruited from the diabetic clinic at Steve Biko Academic Hospital, Pretoria, South Africa. 20 diabetics with cardiovascular disease and 22 without were enrolled to participate. RESULTS AND
CONCLUSION: TF levels were significantly elevated in both diabetic groups when compared to the controls. We suggest that pathologic plasma TF activity, as marker of increased propensity of clot pathology, should be investigated. Agents that might lower TF levels might also possibly lower thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28246677     DOI: 10.1007/s00011-017-1030-x

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  27 in total

Review 1.  Platelet abnormalities in diabetes mellitus.

Authors:  José Luis Ferreiro; Joan Antoni Gómez-Hospital; Dominick J Angiolillo
Journal:  Diab Vasc Dis Res       Date:  2010-10-04       Impact factor: 3.291

Review 2.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

Authors:  Mark A Creager; Thomas F Lüscher; Francesco Cosentino; Joshua A Beckman
Journal:  Circulation       Date:  2003-09-23       Impact factor: 29.690

Review 3.  Coagulation and fibrinolysis in diabetes.

Authors:  S H Alzahrani; R A Ajjan
Journal:  Diab Vasc Dis Res       Date:  2010-09-16       Impact factor: 3.291

Review 4.  Tissue factor, the blood, and the arterial wall.

Authors:  U Rauch; Y Nemerson
Journal:  Trends Cardiovasc Med       Date:  2000-05       Impact factor: 6.677

Review 5.  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?

Authors:  Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2014-08-15

6.  Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.

Authors:  P B Leurs; R van Oerle; B H Wolffenbuttel; K Hamulyak
Journal:  Thromb Haemost       Date:  1997-03       Impact factor: 5.249

7.  Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity.

Authors:  Antonia Sambola; Julio Osende; James Hathcock; Michael Degen; Yale Nemerson; Valentin Fuster; Jill Crandall; Juan Jose Badimon
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

8.  Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus.

Authors:  E Morishita; H Asakura; H Jokaji; M Saito; C Uotani; I Kumabashiri; M Yamazaki; K Aoshima; T Hashimoto; T Matsuda
Journal:  Atherosclerosis       Date:  1996-02       Impact factor: 5.162

9.  Low-grade risk of hypercoagulable state in patients suffering from diabetes mellitus type 2.

Authors:  Barbara Ruszkowska-Ciastek; Alina Sokup; Tomasz Wernik; Piotr Rhone; Krzysztof Góralczyk; Kornel Bielawski; Agata Fijałkowska; Aleksandra Nowakowska; Elżbieta Rhone; Danuta Rość
Journal:  J Zhejiang Univ Sci B       Date:  2015-09       Impact factor: 3.066

10.  Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy.

Authors:  Karthik Balasubramaniam; Girish N Viswanathan; Sally M Marshall; Azfar G Zaman
Journal:  Cardiol Res Pract       Date:  2012-01-05       Impact factor: 1.866

View more
  6 in total

1.  Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.

Authors:  Anke C Fender; Sonja Kleeschulte; Svenja Stolte; Katja Leineweber; Markus Kamler; Johannes Bode; Na Li; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2020-01-07       Impact factor: 17.165

Review 2.  Antiviral anticoagulation.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Bryan H Lin; Marc Horwitz
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

Review 3.  Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.

Authors:  Grzegorz K Jakubiak; Natalia Pawlas; Grzegorz Cieślar; Agata Stanek
Journal:  Int J Environ Res Public Health       Date:  2021-11-15       Impact factor: 3.390

Review 4.  Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis.

Authors:  Xiaoling Li; Nina C Weber; Danny M Cohn; Markus W Hollmann; J Hans DeVries; Jeroen Hermanides; Benedikt Preckel
Journal:  J Clin Med       Date:  2021-05-29       Impact factor: 4.241

5.  Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism.

Authors:  William Hinton; Banne Nemeth; Simon de Lusignan; Ben Field; Michael D Feher; Neil Munro; Lara N Roberts; Roopen Arya; Martin B Whyte
Journal:  Diabet Med       Date:  2020-11-27       Impact factor: 4.359

6.  Mulberry leaf reduces inflammation and insulin resistance in type 2 diabetic mice by TLRs and insulin Signalling pathway.

Authors:  Simin Tian; Min Wang; Chenyue Liu; Hongbin Zhao; Baosheng Zhao
Journal:  BMC Complement Altern Med       Date:  2019-11-21       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.